INNOVATIVE MEDTECH INC (IMTH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed Jan 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMTH SEC filings page.
This page shows INNOVATIVE MEDTECH INC (IMTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business generates revenue, but persistent operating losses sit atop a balance sheet where liabilities overwhelm assets.
Revenue rose from$1.3M in FY2022 to$1.8M in FY2024 while the operating loss narrowed sharply, suggesting FY2022 included an unusually large expense relative to the business’s scale. By FY2024, operating loss was$4.0M while operating cash flow was-$183K , so accounting losses did not translate one-for-one into cash consumption; noncash charges or timing effects are implied, but not identified here.
The balance-sheet contraction was far more severe than the revenue change: total assets fell from
With current assets of
Financial Health Signals
INNOVATIVE MEDTECH INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
INNOVATIVE MEDTECH INC earned $0.09 per diluted share (EPS) in Q4 2025. This represents an increase of 133.3% from the same quarter a year earlier.
Not reported for Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Cash & Balance Sheet
INNOVATIVE MEDTECH INC held $14K in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
IMTH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $428K-10.9% | $456K+3.0% | $455K-4.6% | $433K+2.9% | $481K+25.1% |
| SG&A Expenses | N/A | N/A | $17K+218.9% | $115K-48.9% | -$426K-336.0% | $219K-21.6% | $5K-97.8% | $226K-13.0% |
| Operating Income | N/A | -$57K+93.5% | -$1.1M-1044.8% | -$827K-463.2% | -$2.9M-259.2% | -$865K+6.2% | -$94K+89.9% | -$147K+84.8% |
| EBITDA | N/A | -$49K+94.3% | -$1.1M-1185.8% | -$817K-565.6% | -$2.9M-273.2% | -$849K+7.4% | -$83K+91.0% | -$123K+87.1% |
| Interest Expense | N/A | $42K+38.5% | $30K+189.2% | $30K+35.3% | $25K+1551.4% | $31K-32.1% | $10K-83.8% | $22K-54.1% |
| Income Tax | N/A | $0 | $0 | N/A | N/A | $0 | $0 | N/A |
| Net Income | N/A | -$89K+90.2% | -$1.1M-497.6% | -$884K-435.3% | N/A | -$910K-13.8% | -$188K+80.7% | -$165K+83.5% |
| EPS (Diluted) | $0.09+133.3% | $0.00 | -$0.04 | N/A | -$0.27 | -$0.04 | -$0.01 | N/A |
| Diluted Shares (Avg) | N/A | 53M | 31M | N/A | N/A | 21M | 21M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, EPS (Basic).
IMTH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $250K-61.6% | $1.1M-77.2% | $1.1M-73.9% | $1.3M-72.0% | $652K-85.3% | $4.7M+3.2% | $4.3M-3.8% | $4.6M-0.3% |
| Current Assets | $23K-91.9% | $250K-63.6% | $266K-10.9% | $359K-27.1% | $284K-27.9% | $688K+66.9% | $298K-8.5% | $492K+37.0% |
| Cash & Equivalents | $14K+1459.7% | $351-42.7% | $98-83.0% | $174K-32.1% | $873-22.1% | $613-99.3% | $578-99.3% | $257K+98.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $0-100.0% | N/A | N/A | $166K-26.0% | $161K-28.3% | $221K+7.3% | $196K-1.6% | $225K+21.3% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | $0-100.0% | $178K0.0% | $178K0.0% | $178K0.0% |
| Total Liabilities | $1.3M-78.8% | $6.0M-1.3% | $6.0M+0.1% | $6.3M+4.7% | $6.1M+6.5% | $6.0M-30.6% | $6.0M-24.3% | $6.0M-13.9% |
| Current Liabilities | $1.3M-68.2% | $4.0M+1.8% | $4.0M+5.0% | $4.3M+11.6% | $4.1M+14.7% | $3.9M-38.8% | $3.8M-32.0% | $3.8M-17.6% |
| Non-Current Liabilities | $0-100.0% | $1.9M-7.2% | $2.0M-8.4% | $2.0M-7.3% | $2.0M-6.8% | $2.1M-7.1% | $2.2M-5.8% | $2.2M-6.7% |
| Total Equity | -$1.1M+80.8% | -$4.9M-255.4% | -$4.8M-195.6% | -$5.0M-246.5% | -$5.5M-319.1% | -$1.4M+67.1% | -$1.6M+51.6% | -$1.5M+39.8% |
| Retained Earnings | -$43.3M+2.8% | -$46.7M-23.2% | -$46.6M-25.9% | -$45.4M-23.5% | -$44.6M-21.7% | -$37.9M-6.0% | -$37.0M-5.8% | -$36.8M-8.3% |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
IMTH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | -$18K-6.3% | -$106K+41.9% | $31K+187.7% | $52K-16.6% | -$17K | -$183K-197.0% | -$35K+79.2% |
| Depreciation & Amortization | N/A | $8K-51.7% | $8K-28.1% | $9K-61.2% | $11K-72.3% | $17K+211.5% | $11K+77.6% | $24K+104.6% |
| Stock-Based Compensation | N/A | $0 | $76K | $29K | N/A | $0 | $0 | $0 |
| Capital Expenditures | N/A | N/A | N/A | $12K-87.9% | -$45K+253.9% | $0 | $0 | $95K |
| Free Cash Flow | N/A | N/A | N/A | $19K+114.8% | $7K-85.3% | -$17K | -$183K-197.0% | -$130K+23.0% |
| Investing Cash Flow | N/A | N/A | N/A | -$12K+87.9% | $45K+775.9% | $0 | $0-100.0% | -$95K-1687.8% |
| Financing Cash Flow | N/A | N/A | $77K+197.3% | $41K-81.9% | $716-94.7% | $39K | -$79K-648.7% | $229K+2876.4% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IMTH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | -193.0% | -634.9% | -190.1% | -21.7% | -30.5% |
| Net Margin | N/A | N/A | N/A | -206.3% | N/A | -199.9% | -43.5% | -34.3% |
| Return on Assets | N/A | -8.3%+11.2pp | -99.3%-95.0pp | -69.1%-65.5pp | N/A | -19.5%-1.8pp | -4.3%+17.4pp | -3.6%+18.2pp |
| Current Ratio | 0.02-0.1x | 0.06-0.1x | 0.070.0x | 0.080.0x | 0.070.0x | 0.17+0.1x | 0.080.0x | 0.13+0.1x |
| Asset Turnover | N/A | N/A | N/A | 0.34+0.2x | 0.70+0.6x | 0.100.0x | 0.100.0x | 0.110.0x |
| FCF Margin | N/A | N/A | N/A | 4.5%+31.6pp | 1.6%-9.6pp | -3.7%-3.7pp | -42.3%-27.6pp | -27.1%+17.0pp |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$1.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| INNOVATIVE MEDTECH INC IMTH | FY2025 | N/A | N/A | N/A | $106K | — |
| ENCISION INC ECIA | FY2025 | $6.6M | -$220K | -3.4% | $202K | — |
| REFLECT SCIENTIFIC INC RSCF | FY2023 | $1.1M | -$459K | -42.5% | $5.4M | — |
| UNITED HEALTH PRODUTS INC UEEC | FY2025 | $0 | N/A | N/A | $13.4M | — |
Where INNOVATIVE MEDTECH INC Ranks
Frequently Asked Questions
What are INNOVATIVE MEDTECH INC's total assets?
INNOVATIVE MEDTECH INC (IMTH) had $250K in total assets as of fiscal year 2025, including both current and long-term assets.
What is INNOVATIVE MEDTECH INC's current ratio?
INNOVATIVE MEDTECH INC (IMTH) had a current ratio of 0.02 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is INNOVATIVE MEDTECH INC's P/E ratio?
INNOVATIVE MEDTECH INC (IMTH) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $106K as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is INNOVATIVE MEDTECH INC's price-to-sales ratio?
INNOVATIVE MEDTECH INC (IMTH) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $106K as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is INNOVATIVE MEDTECH INC's debt-to-equity ratio negative or not reported?
INNOVATIVE MEDTECH INC (IMTH) has negative shareholder equity of -$1.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.